fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Stieva-A (00657204), Stieva-A (00578576), Stieva-A (00518182), Vitamin A Acid (01926519). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Tretinoin

Form:

4 of 4 products shown

2 Limited Use · 2 not a benefit

Vitamin A Acid · DIN 01926489 · 0.05% · Gel

Limited Use, Reason for Use code 269 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 269 required
Write on scriptReason for Use code 269 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 269
Reason for Use code 269 For the treatment of acne vulgaris. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vitamin A Acid · DIN 01926489 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2020-09-30 · brand VITAMIN A ACID · ATC D10AD01 TRETINOIN · form Gel · route Topical · ingredients TRETINOIN 0.05 % · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vitamin A Acid: Formulary list price $0.43 per unit (the source does not state the unit; exact figure $0.4266). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926489)

Source record
DIN 01926489: Vitamin A Acid Raw flags: sec12=Y, sec3=Y Item: 842800010; group id 853; item number 2072; lccId 00118; manufacturer id VAL Source form: Gel; strength: 0.05% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4266; ministry $0.4266 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926489 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12544
Shortage status: discontinued (February 7, 2024, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926489
Shortage record checked October 6, 2026

Jamp Tretinoin · DIN 02520036 · 10 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Jamp Tretinoin · DIN 02520036 Manufacturer: Jamp Pharma Corporation; listing date 2023-11-30 Health Canada: Marketed since 2022-08-29 · brand JAMP TRETINOIN · ATC L01XF01 TRETINOIN · form Capsule · route Oral · ingredients TRETINOIN 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Tretinoin: Formulary list price $13.93 per unit (the source does not state the unit; exact figure $13.9284). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02520036)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02520036). DIN 02520036: Jamp Tretinoin Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000164; group id 974; item number 2310; lccId None; manufacturer id JPC Source form: Cap; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $13.9284; ministry $13.9284 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02520036 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100925
Interchangeable products
Vesanoid · DIN 02145839 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520036
Shortage record checked October 6, 2026

Vesanoid · DIN 02145839 · 10 mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; this DIN is on the ministry's EAP drug list: submit an EAP request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
1 brand, same coverage
Vesanoid · DIN 02145839 Manufacturer: Hoffmann-La Roche Limited; listing date 2023-11-30 Health Canada: Marketed since 2013-10-21 · brand VESANOID · ATC L01XF01 TRETINOIN · form Capsule · route Oral · ingredients TRETINOIN 10 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vesanoid: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02145839)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02145839). DIN 02145839: Vesanoid Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 920000164; group id 974; item number 2310; lccId None; manufacturer id HLR Source form: Cap; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02145839 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18080
Interchangeable products
Jamp Tretinoin · DIN 02520036 · $13.9284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02145839
Shortage record checked October 6, 2026

Vitamin A Acid · DIN 01926462 · 0.01% · Gel

Limited Use, Reason for Use code 269 requiredDormant since July 31, 2026 · checked October 5, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 269 required
Write on scriptReason for Use code 269 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 269
Reason for Use code 269 For the treatment of acne vulgaris. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Vitamin A Acid · DIN 01926462 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Dormant since 2026-07-31 · brand VITAMIN A ACID · ATC D10AD01 TRETINOIN · form Gel · route Topical · ingredients TRETINOIN 0.01 % · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Vitamin A Acid: Formulary list price $0.43 per unit (the source does not state the unit; exact figure $0.4266). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01926462)

Source record
DIN 01926462: Vitamin A Acid Raw flags: sec12=Y, sec3=Y Item: 842800031; group id 853; item number 2071; lccId 00118; manufacturer id VAL Source form: Gel; strength: 0.01% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4266; ministry $0.4266 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01926462 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12753
Shortage status: discontinued (May 22, 2024, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926462
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2026 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D10A, D10AD, L01X): coverage varies; not interchangeable

  • Adapalene + benzoyl peroxide (TactuPump): not a benefit
  • Azelaic acid (Finacea): general benefit
  • Anagrelide (Agrylin): limited Use 400, not a benefit, listing status unconfirmed

Alitretinoin

2 Limited Use · 2 not a benefit

Hanzema · DIN 02477432 · 10 mg · capsule

Limited Use, Reason for Use code 442 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 442 required
Write on scriptReason for Use code 442 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Hanzema · DIN 02477432 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-06-09 · brand HANZEMA · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 10 MG · company Dr. reddy's laboratories inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Hanzema: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9868). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477432)

Source record
DIN 02477432: Hanzema Raw flags: sec12=Y, sec3=Y Item: 843600092; group id 856; item number 2076; lccId 00234; manufacturer id DRR Source form: Cap; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $16.9868; ministry $16.9868 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477432 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96841
Interchangeable products
Toctino · DIN 02337630 · not recorded
Shortage status: resolved shortage (ended June 28, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477432
Shortage record checked October 6, 2026

Hanzema · DIN 02477440 · 30 mg · capsule

Limited Use, Reason for Use code 442 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 442 required
Write on scriptReason for Use code 442 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Hanzema · DIN 02477440 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-06-09 · brand HANZEMA · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 30 MG · company Dr. reddy's laboratories inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Hanzema: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9868). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477440)

Source record
DIN 02477440: Hanzema Raw flags: sec12=Y, sec3=Y Item: 843600093; group id 856; item number 2077; lccId 00234; manufacturer id DRR Source form: Cap; strength: 30mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $16.9868; ministry $16.9868 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477440 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96842
Interchangeable products
Toctino · DIN 02337649 · not recorded
Shortage status: resolved shortage (ended April 15, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477440
Shortage record checked October 6, 2026

Toctino · DIN 02337630 · 10 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.Discontinued July 14, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Toctino · DIN 02337630 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2013-04-30 Health Canada: Cancelled post market since 2023-07-14 · brand TOCTINO · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 10 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Toctino: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337630)

Source record
DIN 02337630: Toctino Raw flags: notABenefit=Y, sec3=Y Item: 843600092; group id 856; item number 2076; lccId 00234; manufacturer id GSK Source form: Cap; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337630 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82321
Interchangeable products
Hanzema · DIN 02477432 · $16.9868
Shortage status: discontinued (June 30, 2023, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337630
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 14, 2023 — choose a marketed DIN from the same-category list.

Toctino · DIN 02337649 · 30 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.Discontinued July 14, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Toctino · DIN 02337649 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2013-04-30 Health Canada: Cancelled post market since 2023-07-14 · brand TOCTINO · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 30 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Toctino: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337649)

Source record
DIN 02337649: Toctino Raw flags: notABenefit=Y, sec3=Y Item: 843600093; group id 856; item number 2077; lccId 00234; manufacturer id GSK Source form: Cap; strength: 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337649 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82322
Interchangeable products
Hanzema · DIN 02477440 · $16.9868
Shortage status: discontinued (June 30, 2023, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337649
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 14, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D10A, D10AD, L01X): coverage varies; not interchangeable

  • Adapalene + benzoyl peroxide (TactuPump): not a benefit
  • Azelaic acid (Finacea): general benefit
  • Anagrelide (Agrylin): limited Use 400, not a benefit, listing status unconfirmed

Isotretinoin

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription

Accutane · DIN 00582344 · 10 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Accutane · DIN 00582344 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 2026-07-22 · brand ACCUTANE · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Cheplapharm schweiz gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00582344)

Source record
DIN 00582344: Accutane Raw flags: sec3=Y Item: 843600035; group id 864; item number 2086; lccId None; manufacturer id HLR Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.9738; ministry $0.9313 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00582344 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5128 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Clarus · DIN 02257955 · $0.9313
Shortage status: resolved shortage (ended April 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00582344
Shortage record checked October 6, 2026

Clarus · DIN 02257955 · 10 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Clarus · DIN 02257955 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-07-19 Health Canada: Marketed since 2010-03-01 · brand CLARUS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clarus: Formulary list price $0.93 per unit (the source does not state the unit; exact figure $0.9313). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02257955)

Source record
DIN 02257955: Clarus Raw flags: sec3=Y Item: 843600035; group id 864; item number 2086; lccId None; manufacturer id MYL Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.9313; ministry $0.9313 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02257955 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74319 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Accutane · DIN 00582344 · $0.9313
Shortage status: resolved shortage (ended August 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02257955
Shortage record checked October 6, 2026

Epuris · DIN 02396971 · 10 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Epuris · DIN 02396971 Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27 Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 10 MG · company Cipher pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Epuris: Formulary list price $1.54 per unit (the source does not state the unit; exact figure $1.5441). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396971)

Source record
DIN 02396971: Epuris Raw flags: sec3=Y Item: 843600095; group id 864; item number 2087; lccId None; manufacturer id CIP Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $1.5441; ministry $1.5441 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396971 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88198 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396971
Shortage record checked October 6, 2026

Epuris · DIN 02396998 · 20 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Epuris · DIN 02396998 Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27 Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 20 MG · company Cipher pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Epuris: Formulary list price $2.14 per unit (the source does not state the unit; exact figure $2.1365). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02396998)

Source record
DIN 02396998: Epuris Raw flags: sec3=Y Item: 843600096; group id 864; item number 2088; lccId None; manufacturer id CIP Source form: Cap; strength: 20mg Recorded listing: General benefit Source prices (unrounded): $2.1365; ministry $2.1365 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02396998 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88199 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02396998
Shortage record checked October 6, 2026

Epuris · DIN 02397005 · 30 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Epuris · DIN 02397005 Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27 Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 30 MG · company Cipher pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Epuris: Formulary list price $2.69 per unit (the source does not state the unit; exact figure $2.6871). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02397005)

Source record
DIN 02397005: Epuris Raw flags: sec3=Y Item: 843600097; group id 864; item number 2089; lccId None; manufacturer id CIP Source form: Cap; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $2.6871; ministry $2.6871 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02397005 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88200 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397005
Shortage record checked October 6, 2026

Accutane · DIN 00582352 · 40 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Accutane · DIN 00582352 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Marketed since 2025-09-05 · brand ACCUTANE · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Cheplapharm schweiz gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00582352)

Source record
DIN 00582352: Accutane Raw flags: sec3=Y Item: 843600034; group id 864; item number 2090; lccId None; manufacturer id HLR Source form: Cap; strength: 40mg Recorded listing: General benefit Source prices (unrounded): $1.9870; ministry $1.9003 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00582352 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5129 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Clarus · DIN 02257963 · $1.9003
Shortage status: resolved shortage (ended April 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00582352
Shortage record checked October 6, 2026

Clarus · DIN 02257963 · 40 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Clarus · DIN 02257963 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2006-07-19 Health Canada: Marketed since 2010-03-01 · brand CLARUS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clarus: Formulary list price $1.90 per unit (the source does not state the unit; exact figure $1.9003). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02257963)

Source record
DIN 02257963: Clarus Raw flags: sec3=Y Item: 843600034; group id 864; item number 2090; lccId None; manufacturer id MYL Source form: Cap; strength: 40mg Recorded listing: General benefit Source prices (unrounded): $1.9003; ministry $1.9003 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02257963 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74320 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Interchangeable products
Accutane · DIN 00582352 · $1.9003
Shortage status: resolved shortage (ended August 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02257963
Shortage record checked October 6, 2026

Epuris · DIN 02397013 · 40 mg · capsule

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Epuris · DIN 02397013 Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27 Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 40 MG · company Cipher pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Epuris: Formulary list price $3.15 per unit (the source does not state the unit; exact figure $3.1503). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02397013)

Source record
DIN 02397013: Epuris Raw flags: sec3=Y Item: 843600098; group id 864; item number 2091; lccId None; manufacturer id CIP Source form: Cap; strength: 40mg Recorded listing: General benefit Source prices (unrounded): $3.1503; ministry $3.1503 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02397013 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88201 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02397013
Shortage record checked October 6, 2026

Other products in the same Health Canada class (D10A, D10AD, L01X): coverage varies; not interchangeable

  • Adapalene + benzoyl peroxide (TactuPump): not a benefit
  • Azelaic acid (Finacea): general benefit
  • Anagrelide (Agrylin): limited Use 400, not a benefit, listing status unconfirmed
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (84:28 Keratolytic Agents) and how they are covered

Matched class: 84:28 Keratolytic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 84:28 Keratolytic Agents

ADAPALENE & BENZOYL PEROXIDE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.1%w/w & 2.5%w/w · Top Gel Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:28
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:36 Miscellaneous Skin and Mucous Membrane Agents

Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

ADAPALENE & BENZOYL PEROXIDE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.3% w/w & 2.5% w/w · Top Gel

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

FLUOROURACIL

· 1 products · General benefit · strengths: 5% · Cr

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr

RISANKIZUMAB

· 3 products · Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:36 and 2 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ANAGRELIDE HCL

· 3 products · Listed, not a benefit (1), Limited Use, codes 400 (1), Temporary benefit (1) · strengths: 0.5mg · Cap

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS and CLINICAL USES VITAMIN A ACID Gel is indicated for topical application in the treatment of acne vulgaris, primarily Grades I, II and III in which comedones, papules and pustules predominate. https://pdf.hres.ca/dpd_pm/00058250.PDF PM date: September 29, 2020 Source product: VITAMIN A ACID; DIN 01926489; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE HANZEMA (alitretinoin) is indicated for the treatment of severe chronic hand eczema refractory to high potency topical corticosteroids in adults. HANZEMA should only be prescribed by physicians knowledgeable in the use and monitoring requirements of systemic retinoids, who understand the risk of teratogenicity in females of child bearing potential (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions and Special Populations, Women of Child Bearing Potential). Geriatrics (> 65 years of age): Clinical trial experience has not identified differences in responses between elderly and other patients. However clinical studies of alitretinoin did not include sufficient numbers of subjects aged 65 years and over to determine with certainty whether they respond differently from younger subjects (ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Pharmacokinetics in special populations). HANZEMA Page 3 of 40 Pediatrics (< 18 years of age): HANZEMA is not recommended for use in patients under 18 years of age. https://pdf.hres.ca/dpd_pm/00067982.PDF PM date: October 20, 2022 Source product: HANZEMA; DIN 02477432; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS ACCUTANE™ (isotretinoin) is indicated for the treatment of: • Severe Nodular and/or Inflammatory Acne • Acne Conglobata • Recalcitrant Acne Because of significant side effects associated with its use, ACCUTANE should be reserved for patients where the conditions listed above are unresponsive to conventional first line therapies. ACCUTANE should only be prescribed by physicians knowledgeable in the use of retinoids systemically, who understand the risk of teratogenicity in females of child bearing age and who are experienced in counselling young adults for whom ACCUTANE is generally indicated (see 2 CONTRAINDICATIONS, 3 SERIOUS WARNINGS AND PRECAUTIONS BOX and 7.1.1 Pregnant Women). A careful assessment of the patient’s mental state should be made, including whether or not they have a history of previous psychiatric illness (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Psychiatric). It is strongly recommended that each ACCUTANE prescription be limited to a one-month supply in order to encourage patients to return for follow-up to monitor side-effects. The pharmacist must ensure that: • Prescriptions of ACCUTANE for women of child-bearing potential sho… https://pdf.hres.ca/dpd_pm/00081681.PDF PM date: SEP 05, 2025 Source product: ACCUTANE; DIN 00582344; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Vitamin A Acid · DIN 01926489 Shortage status: discontinued (2024-02-07, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926489

Check this DIN again

Vitamin A Acid · DIN 01926462 Shortage status: discontinued (2024-05-22, reported by BAUSCH HEALTH, CANADA INC.); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01926462

Check this DIN again

Toctino · DIN 02337630 Shortage status: discontinued (2023-06-30, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337630

Check this DIN again

Toctino · DIN 02337649 Shortage status: discontinued (2023-06-30, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337649

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Jamp Tretinoin, Vesanoid, Toctino: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026